Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
12 avr. 2023 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
PDC Launches Comfort Cushion™ Mammography Pad to Help Breast Health Centers Improve the Patient Experience
25 oct. 2022 09h00 HE
|
PDC
VALENCIA, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDC, a global leader of innovative identification and patient safety solutions, announced today the launch of the Comfort Cushion™ Mammography Pad...
L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale
12 sept. 2022 07h30 HE
|
Theratechnologies
Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
12 sept. 2022 07h30 HE
|
Theratechnologies
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...
PDC Introduces Ident-Alert® IV Port Clips to Help Anesthesiologists Prevent Medication Errors
02 nov. 2021 18h07 HE
|
PDC - A Brady Business
VALENCIA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- PDC, a global leader of innovative identification and patient safety solutions, announced today the launch of Ident-Alert® IV Port Clips for...
The Professional Development Consortium Awards Language Learning Leader Rosetta Stone with Provider of Training Excellence Accreditation
19 mars 2018 08h00 HE
|
Rosetta Stone
Arlington, VA, March 19, 2018 (GLOBE NEWSWIRE) -- Technology-based learning solutions provider, Rosetta Stone Inc. (NYSE: RST) today announced that it has been awarded full accreditation as a...
Mission Ready's Protect The Force Wins TEEX Award
27 oct. 2016 09h00 HE
|
Mission Ready Services Inc.
VANCOUVER, BC--(Marketwired - October 27, 2016) - Mission Ready Services Inc. ("Mission Ready" or the "Company") (TSX VENTURE: MRS) is pleased to announce that its subsidiary Protect The Force Inc....